Brinker Capital Investments LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 3.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,297 shares of the biotechnology company's stock after buying an additional 150 shares during the period. Brinker Capital Investments LLC's holdings in Sarepta Therapeutics were worth $475,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the business. Great West Life Assurance Co. Can increased its holdings in shares of Sarepta Therapeutics by 126.2% in the 3rd quarter. Great West Life Assurance Co. Can now owns 10,774 shares of the biotechnology company's stock worth $1,187,000 after buying an additional 6,011 shares during the last quarter. M&G Investment Management Ltd. bought a new position in Sarepta Therapeutics during the 3rd quarter valued at about $1,719,000. Dupont Capital Management Corp grew its holdings in Sarepta Therapeutics by 70.1% during the 3rd quarter. Dupont Capital Management Corp now owns 7,554 shares of the biotechnology company's stock valued at $835,000 after purchasing an additional 3,114 shares during the last quarter. NJ State Employees Deferred Compensation Plan bought a new position in Sarepta Therapeutics during the 3rd quarter valued at about $763,000. Finally, EFG Asset Management North America Corp. bought a new position in Sarepta Therapeutics during the 3rd quarter valued at about $2,364,000. 87.31% of the stock is currently owned by institutional investors.
Get Sarepta Therapeutics alerts:Insider Transactions at Sarepta Therapeutics
In other news, Director Stephen Mayo sold 858 shares of the company's stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $109.92, for a total value of $94,311.36. Following the completion of the sale, the director now owns 6,387 shares of the company's stock, valued at approximately $702,059.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.40% of the company's stock.
Sarepta Therapeutics Price Performance
Shares of SRPT opened at $128.37 on Wednesday. The company has a 50 day moving average price of $122.74 and a 200-day moving average price of $111.59. Sarepta Therapeutics, Inc. has a fifty-two week low of $61.28 and a fifty-two week high of $134.08. The stock has a market capitalization of $11.27 billion, a PE ratio of -15.64 and a beta of 1.04. The company has a debt-to-equity ratio of 3.58, a quick ratio of 3.99 and a current ratio of 4.36.Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($2.94) earnings per share for the quarter, missing the consensus estimate of ($1.21) by ($1.73). Sarepta Therapeutics had a negative return on equity of 97.37% and a negative net margin of 81.76%. The business had revenue of $230.30 million during the quarter, compared to analysts' expectations of $234.55 million. During the same period in the previous year, the company posted ($0.60) EPS. Sarepta Therapeutics's revenue for the quarter was up 21.6% on a year-over-year basis. Equities analysts predict that Sarepta Therapeutics, Inc. will post -8.09 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts recently commented on SRPT shares. StockNews.com started coverage on shares of Sarepta Therapeutics in a report on Wednesday, October 12th. They set a "hold" rating on the stock. Morgan Stanley upped their price target on shares of Sarepta Therapeutics from $135.00 to $141.00 and gave the company an "equal weight" rating in a report on Thursday, October 13th. UBS Group upgraded shares of Sarepta Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the company from $100.00 to $158.00 in a report on Friday, December 16th. The Goldman Sachs Group upped their price target on shares of Sarepta Therapeutics from $152.00 to $171.00 and gave the company a "buy" rating in a report on Thursday, November 3rd. Finally, Cowen upped their price target on shares of Sarepta Therapeutics from $114.00 to $125.00 in a report on Wednesday, January 11th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $150.14.
About Sarepta Therapeutics
(Get Rating)
Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Featured Articles
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.